Search

1 | INTRODUCTION Decades of definitions of Health Services Research are broadly consistent with the definition articulated a quarter of a century ago by the National Academy of Sciences, wherein [...]

Objectives. To document the numbers and types of interorganizational partnerships within the national patient safety domain, changes over time in these networks, and their potential for disseminating patient safety knowledge and practices. Data Sources. Self-reported information gathered from representatives of national-level organizations active in promoting patient safety. Study Design. Social network analysis was used to examine the structure and composition of partnership networks and changes between 2004 and 2006. Data Collection. Two rounds of structured telephone interviews (n = 35 organizations in 2004 and 55 in 2006). Principal Findings. Patient safety partnerships expanded between 2004 and 2006. The average number of partnerships per interviewed organization increased 40 percent and activities per reported partnership increased over 50 percent. Partnerships increased in all activity domains, particularly dissemination and tools development. Fragmentation of the overall partnership network decreased and potential for information flow increased. Yet network centralization increased, suggesting vulnerability to partnership failure if key participants disengage. Conclusions. Growth in partnerships signifies growing strength in the capacity to disseminate and implement patient safety advancements in the U.S. health care system. The centrality of AHRQ in these networks of partnerships bodes well for its leadership role in disseminating information, tools, and practices generated by patient safety research projects. Key Words. Patient safety, partnership, collaboration, dissemination, network analysis, BACKGROUND Since the publication of the Institute of Medicine's landmark report, To Err Is Human: Building a Safer Health System (Institute of Medicine 2000), national and local efforts have been [...]

If you've been bodybuilding for more than a decade, you will likely remember the hype that surrounded a simple supplement known as ZMA at the turn of the millennium. A [...]

The prospective future of the post-earthquake Kobe, a western Japanese city, is evaluated. As Kobe slowly rebuilt its battered infrastructure, the concentration of major drug makers and universities in the region helps the city transform itself into a center for advanced medical research.

Research and Markets (http://www.researchandmarkets.com/research/7f327f/commercial_insight) has announced the addition of the "Commercial Insight: Parkinson's Disease - Japan and Europe to Drive Total Market Growth" report to their offering (see also Research [...]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajog.2009.07.016 Byline: Katherine R. Goetzinger, Ashima Singla, Sabrina Gerkowicz, Jeffrey M. Dicke, Diana L. Gray, Anthony O. Odibo Keywords: fetal growth; free [beta]-hCG; large for gestational age; PAPP-A; small for gestational age Abstract: To evaluate the association between first-trimester serum analytes, pregnancy-associated plasma protein A and free beta-human chorionic gonadotropin, and fetal growth disorders, and to determine whether a prediction model for these growth disorders can be developed. Author Affiliation: Department of Obstetrics and Gynecology, Washington University, St. Louis, MO Article History: Received 28 February 2009; Revised 23 May 2009; Accepted 8 July 2009 Article Note: (footnote) Reprints not available from the authors., Cite this article as: Goetzinger KR, Singla A, Gerkowicz S, et al. The efficiency of first-trimester serum analytes and maternal characteristics in predicting fetal growth disorders. Am J Obstet Gynecol 2009;201:412.e1-6.

Research and Markets (http://www.researchandmarkets.com/research/a25937/forecast_insight) has announced the addition of the "Forecast Insight: Inflammatory Bowel Disease - New product launches sustain long-term market growth" report to their offering (see also Research [...]

According to recent research from Manchester, the United Kingdom, "3-M syndrome is an autosomal-recessive primordial growth disorder characterized by significant intrauterine and postnatal growth restriction. Mutations in the CUL7 gene [...]

Byline: David A. Patten New data on long-term drug therapies for hyperactive children link the commonly prescribed medications with stunted growth -- a result doctors have suspected for years, but [...]

BEEF cattle can lose 74kg a year in growth potential due to pneumonia- induced lung damage, according to new study revealed this week that concluded farmers were not treating the [...]

In 2002, the makeup and cosmetics industry in the United States generated nearly $30 billion of revenue. (1) Sales of mascara, a product that is used to lengthen, darken or [...]

Baltimore -- Findings from a series of preclinical studies show that digoxin (Lanoxin) can affect tumor biology and interfere with tumor growth and may provide a basis for conducting clinical [...]

Infection control concerns have recently caught the nation's attention with media reports specifically related to the methicillin-resistant Staphylococcus aureus (MRSA) 'superbug,' which led to the death of a Virginia teen [...]

As cases of diabetes grow to near-epidemic levels in America, spending on drugs for the disease is predicted to jump 70% through 2009, experts at Medco Health Solutions Inc. say. [...]

Arizona is becoming a place of clinical research, as many pharmaceutical companies are being multisided national and international clinical trials to assess the safety and efficacy of drugs in 2005. Arizona is moving forward in the biosciences in many areas including clinical research and Arizona scientists are leading edge of clinical research and drug development.